ESMO 2023 | Management of residual disease in triple negative breast cancer

Federica Giugliano, MD, Gustave Roussy Cancer Center, Villejuif, France, outlines the case presentation of a patient with triple-negative breast cancer and a BRCA-1 mutation. The patient experienced residual disease following neoadjuvant chemoimmunotherapy according to the KEYNOTE 522 study (NCT03036488) with pembrolizumab and olaparib, and Dr Giugliano’s studies focus on the management of this residual disease. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.